DocGo (DCGO) Q4 2025 Earnings Call Transcript

DocGo reported Q4 revenue of $74.9M (down from $120.8M, roughly -38% y/y) and an adjusted EBITDA loss of $11.3M, driven by the wind-down of migrant programs; full-year 2026 guidance was raised to $290M–$310M and adjusted EBITDA loss narrowed to $5M–$10M. Management wrote goodwill of $49.5M and intangibles of $22.6M to zero (noncash GAAP impairments), ended the year with $68.3M cash (down from $95.2M), and still expects to collect $20M of migrant-related receivables. The company highlighted SteadyMD momentum (Q4 contribution $6.1M; full-year SteadyMD revenues guided to $25M–$30M), operational efficiency programs targeting $5M–$6M savings in 2026 and $20M–$24M annualized by 2027, and has initiated a strategic review with an investment bank retained.

Analysis

The accounting write-downs function as an optical reset that increases strategic optionality: by removing legacy intangible carrying values, the company becomes a cleaner M&A target (or easier to carve up) because an acquirer would not inherit large near-term amortization charges. That creates a binary outcome over the next 3–9 months — a strategic transaction at a meaningful control premium is plausible, but so is creditor-driven pressure if working capital shortfalls persist. Market participants are likely to misprice that binary as a steady-state operating problem rather than a time-limited liquidity event.

Operationally, the firm has built several high-ROIC levers — automation, tighter staffing, and an attachable virtual-care asset — which convert incremental revenue into disproportionately higher EBITDA. The real optionality is cross-selling the virtual-care platform into route-based visits (higher lifetime value per patient) and compressing field labor costs by reducing outsourced rides; those are multi-quarter margin tailwinds rather than one-off benefits. Competitors that lack an integrated physical+virtual footprint face a strategic disadvantage, which raises the probability of strategic interest from payers or national care platforms looking to close that gap.

Liquidity and covenant risk are the key near-term overhangs and set the timeline for any forced outcome. Collections timing and creditor negotiations will likely determine whether management achieves a voluntary strategic sale or a distressed alternative; monitor covenant waivers, lender language, and any untimely vendor pushback over the next 60–120 days. For investors, the opportunity is a classic event-driven trade with asymmetric upside if the strategic review yields a buyer and materially negative downside if covenant remediation fails and borrowing costs spike.

Key Decisions for Investors

• Event-driven small-core long DCGO (ticker: DCGO) — size 0.5%–1.0% NAV entry now, add on confirmed HPD/migrant-receivable collections or covenant waiver. Hedge with a 6–9 month protective put to cap downside; target asymmetric upside from a strategic sale or margin normalization over 3–12 months (expect >2x upside vs limited downside to put strike).
• Long DCGO Jan‑2027 calls (LEAP) funded with a short-dated put sale — use options to capture M&A optionality while defining cash outlay. Allocate conservative notional (max 0.25% NAV exposure) and roll if process extends beyond nine months; plan to monetize into any formal process announcement.
• Pair trade for risk-off exposure: Long DCGO (small size) / Short larger telehealth peer (example: TDOC) — rationale: consolidation premium should compress vs incumbents if strategic buyers pursue integrated home+virtual assets. Keep pair neutral to health-care beta; rebalance after any acquisition rumor or earnings surprise.
• Event alerts & stop triggers — set hard alerts for (1) confirmation of migrant-receivable cash inflows, (2) formal covenant waivers, and (3) launch/termination of the strategic review. If covenant remediation fails or cash runway shortens materially, close long positions and consider shorting on technical breakdowns within 24–72 hours.